Sign In  |  Register  |  About Mill Valley  |  Contact Us

Mill Valley, CA
September 01, 2020 1:29pm
7-Day Forecast | Traffic

  • Search Hotels in Mill Valley

  • CHECK-IN:
  • CHECK-OUT:
  • ROOMS:
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Mind Medicine Mindmed Inc (NQ: MNMD )

7.560 UNCHANGED
Streaming Delayed Price Updated: 4:00 PM EST, Nov 22, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Mind Medicine Mindmed Inc

< Previous 1 2
...
25 26 27 28 29 30 31 32 Next >
Could Mind Medicine Be a Millionaire-Maker Stock?
Yes, but with the chance of great reward comes substantial risk. 
Via The Motley Fool
Recent Surge for Intellectual Property & Patents in Psychedelic Therapies & Drug Development
Via FinancialNewsMedia
Topics Intellectual Property
Exposures Intellectual Property
Psyched: Atai's $214M IPO, MindMed CEO Resigns, Field Trip Applies To Nasdaq, Cybin And Novamind Target Frontline Health Workers
Atai Launches $214 Million Nasdaq IPO Offering Psychedelics biotech platform Atai life Sciences has announced an initi... 
Via Benzinga
Topics Initial Public Offering
Exposures Securities Market
J.R. Rahn Steps Down As MindMed CEO
Mind Medicine Inc. (NASDAQ:MNMD), more commonly known as M... 
Via Benzinga
Mind Medicine Stock Might Still Be Worth the Risk Here
The rampant addiction crisis in America requires a new effective solution, which may suit MNMD stock well. 
Via InvestorPlace
EXCLUSIVE: Psychedelics Pioneer J.R. Rahn Unpacks Decision To Leave MindMed As CEO
Mind Medicine (MindMed) Inc (NASDAQ: MNMD) (NEO: MMED), a biotech company focused on the field of psychedelics, formally announced this week that J.R. Rahn, the company’s co... 
Via Benzinga
Here's How This Psychedelic Drug CEO Sees The Industry Evolving
Competition within legal psychedelic drugs has only barely taken shape. Companies focused on therapy will be the ultimate winners, one CEO said. 
Via Investor's Business Daily
Why Shares of MindMed Dropped 13% in May
Froth from its uplisting is having an impact. 
Via The Motley Fool
What Do You Really Know About Psychedelics And Psychedelics Stocks?
According to a new poll conducted by Hill-HarrisX, 65% of registered voters say psychedelic substances do not have medical use. That... 
Via Benzinga
Why the North America Psychedelic Drugs Market is Expected to Grow With the Fastest CAGR for Next Several Years
Via FinancialNewsMedia
Topics Law Enforcement
Exposures Legal
Psyched: First Psychedelics ETF Comes To The US, Bills Move Forward In Texas, California and New York
Psychedelics ETFs Are Gaining Traction Defiance ETFs launched the “Next Gen Altered Experience ETF,” the ... 
Via Benzinga
The Mind Medicine Stock Story Has an Awful Lot of Holes in It
MNMD stock has immense potential, but the plethora of risks surrounding it limit its attractiveness at this time. 
Via InvestorPlace
Psychedelic Drug Stocks: A Big Healthcare Footprint At A Small Price
Fuelled by hundreds of millions in startup capital, psychedelic drug companies are powering a Revolution in healthcare. But with the sector currently in a trough, investors can still enter at... 
Via Talk Markets
Cannabis Countdown: Top 10 Marijuana and Psychedelic Stock News Stories of the Week
Welcome to the Cannabis... 
Via Benzinga
Topics Cannabis
Exposures Cannabis
Mind Medicine Stock Is Not a Trip To Take Just Yet
Psychedelic drugs may eventually be a big market. However, investors in MNMD stock may be getting in a little too early. 
Via InvestorPlace
Topics Cannabis Law Enforcement
Exposures Cannabis Legal
MindMed Collaborates with Nextage Therapeutics for Brain Targeting Liposome System
MindMed (NASDAQ: MNMD) and Israel-listed Nextage Therapeutics have entered into an exclusive collaborative development program to optimize the delivery of... 
Via Benzinga
Psyched: MindMed To Begin Mescaline Trials and Deepak Chopra Partnership, Seelos And Cybin Advance Clinical Research
MindMed’s News Spree: Mescaline Trials, Chopra Foundation Partnership and LSD Research MindMed (NASDAQ: 
Via Benzinga
Cannabis Movers & Shakers: The Parent Company, MindMed, Australis, Flourish Software
The Parent Company Welcomes Desiree Perez To Its Board TPCO Holding Corp. (OTCQX: 
Via Benzinga
Topics Cannabis
Exposures Cannabis
The Jury’s Still Out on Psychedelics Play MindMed Stock
Selling off after its NASDAQ uplisting, it's hard to tell whether MNMD stock will soar higher following recent positive developments. 
Via InvestorPlace
MindMed To Conduct The First Modern Research On Mescaline In Switzerland
MindMed (NASDAQ: MNMD) (NE... 
Via Benzinga
Psychedelic Drug Developer Sets Sights On This Age-Old Hallucinogen
MindMed stock fell after it said a Swiss ethics committee cleared it to begin a study on the effects of the hallucinogen mescaline. 
Via Investor's Business Daily
22 Stocks Moving in Wednesday's Pre-Market Session
Gainers Advaxis, Inc. (NASDAQ: ADXS) shares rose 29.6% to $0.6289 in pre-market trading after jumping over 14% on Tuesday. LightPath Technologies, Inc. (NASDAQ: LPTH) rose 16.3%... 
Via Benzinga
Strong Cash Balance Should Provide a Foundation for MindMed Stock
Now that it has joined the Nasdaq Exchange, MNMD stock will have its ups and downs but firm financials should instill shareholder confidence. 
Via InvestorPlace
MNMD Stock: The Big News That Has MindMed Investors Psyched Today
MindMed (MNMD) stock is getting a boost on Monday following news from the FDA that allows the company to continue development. 
Via InvestorPlace
Exposures Product Safety
MindMed Stock Moves Higher After Finalizing Generalized Anxiety Disorder As Initial Indication For LSD Trial
After receiving Type C Meeting Responses from the FDA, MindMed (NASDAQ: MNMD) has selected Generalized Anxiety Disorder as an initial indication for its Project Lucy,... 
Via Benzinga
Exposures Product Safety
Psyched: MindMed And Compass Q1 Earnings, FDA Approves Therapists Taking MDMA, Wesana Health Goes Public
Two of the most prominent companies in the psychedelics space released their financials for the first quarter of 2021. Compass Pa... 
Via Benzinga
Exposures Product Safety
EXCLUSIVE: MindMed CEO Talks Mission To 'Discover, Develop And Deploy' Psychedelics
Mind Medicine Inc (NASDAQ: MNMD) was started to address mental wellness, CEO and co-founder J.R. Rahn told Benzinga's Global Small Cap Conference Thursday. MindMed... 
Via Benzinga
Benzinga Global Small Cap Conference: How Do Investors Pick Winners In The Psychedelics Space?
Simeon Schnapper, a managing partner at JLS Fund, took 30 minutes from his busy schedule to share his insights into what makes a w... 
Via Benzinga
Video: Psychedelic Stocks With JLS Fund's Simeon Schnapper & MindMed's JR Rahn
During the Benzinga Global Small-Cap Conference on Thursday morning, psychedelics executives discussed the markets and companies' prospects. 
Via Benzinga
Cannabis Countdown: Top 10 Marijuana And Psychedelic Stock News Stories Of The Week
Welcome to the Cannabis Countdo... 
Via Benzinga
Topics Cannabis
Exposures Cannabis
< Previous 1 2
...
25 26 27 28 29 30 31 32 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.
 
 
About Us | Contact Us | Privacy Policy | User Agreement | Advertise With Us | Site Map
Copyright © 2010-2020 MillValley.com & California Media Partners, LLC. All rights reserved.